Rapid intravenous administration of granisetron prior to chemotherapy is not arythmogenic: Results of a pilot study

European Journal of Cancer

Volumn 39, Issue 7, 2003, Pages 927-931

  Aapro, M ^a   Bourke, J P ^b  

^a CLINIQUE DE GENOLIER   (Switzerland)

^b FREEMAN HOSPITAL   (United Kingdom)

Author keywords

Antiemetic; Arrhythmia; Cardiac repolarisation; Cardiovascular; Chemotherapy; ECG; Granisetron; QT interval

Indexed keywords

CARDIOTOXIN; DEXAMETHASONE; GRANISETRON;

ADULT; AGED; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CANCER THERAPY; CARDIOVASCULAR EFFECT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ELECTROCARDIOGRAM; FEMALE; HEART ARRHYTHMIA; HEART REPOLARIZATION; HUMAN; MALE; PRIORITY JOURNAL; QT INTERVAL; RAPID INTRAVENOUS ADMINISTRATION; RISK ASSESSMENT;

EID: 0037403266     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00120-5     Document Type: Article

References (26)

1. Ewer M.S., Benjamin R.S. Cardiac Complications. Holland J.F., Bast R.C., Morton D.L.et al. Cancer Medicine. 4th edn. 1997;3197-3215 Williams and Wilkins, Baltimore, MD.
2. 3 receptor antagonist antiemetics. is there cause for concern? Oncologist. 7:2002;65-72.
3. Cowan J.D., Neidhart J., McClure S.et al. Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer. a Southwest Oncology Group Study J. Natl. Cancer Inst. 83:1991;1077-1084.
4. Faulds D., Balfour J.A., Chrisp P., Langtry H.D. Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs. 41:1991;400-449.
5. Rowinsky E.K., Donehower R.C. Paclitaxel (taxol). N. Engl. J. Med. 333:1995;1004-1014.
6. Yancik R. Cancer burden in the aged. an epidemiologic and demographic overview Cancer. 80:1997;1273-1283.
7. Wei J.Y. Cardiovascular comorbidity in the older cancer patient. Semin. Oncol. 22(Suppl. 2):1995;9-10.
8. O'Brien B.J., Rusthoven J., Rocchi A.et al. Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs. survey of five Canadian centres Can. Med. Assoc. J. 149:1993;296-302.
9. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am. J. Health-Syst. Pharm. 56:1999;729-764.
10. Gralla R.J., Osoba D., Kris M.G.et al. Recommendations for the use of antiemetics. evidence-based, clinical practice guidelines J. Clin. Oncol. 17:1999;2971-2994.
11. Perez E.A., Hesketh P., Sandbach J.et al. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. a multicenter, double-blind, randomized parallel study J. Clin. Oncol. 16:1998;754-760.
12. Kris M.G., Grunberg S.M., Gralla R.J.et al. Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. J. Clin. Oncol. 12:1994;1045-1049.
13. Lifsey D.S., Gralla R.J., Clark R.A., Kline R.C. Electrocardiographic changes with serotonin antagonist antiemetics. rate of occurrence and clinical relevance Proc. Am. Soc. Clin. Oncol. 12:1993;463. (abstr 1611).
14. Gray G.W., McLellan T.M., Ducharme M.B. Granisetron shows no pro-arrhythmic effect in normal subjects during or after exercise in a hot environment. Aviat. Space Environ. Med. 67:1996;759-761.
15. Boike S.C., Ilson B., Zariffa N.et al. Cardiovascular effects of i.v. Granisetron at two administration rates and of ondansetron in healthy adults. Am. J. Health Syst. Pharm. 54:1997;1172-1176.
16. Carmichael J., Philip P.A., Forfar C., Harris A.L. An open study to assess the safety, tolerance and pharmacokinetics of an intravenous infusion of granisetron given at 3 mg over 30 s in patients receiving chemotherapy for malignant disease. Cancer Chemother. Pharmacol. 37:1995;134-138.
17. Jantunen I.T., Kataja V.V., Muhonen T.T.et al. Effects of granisetron with doxorubicin or epirubicin on ECG intervals. Cancer Chemother. Pharmacol. 37:1996;502-504.
18. Day C.P., McComb J.M., Campbell R.W.F. QT dispersion. an indication of arrhythmia risk in patients with long QT intervals Br. Heart J. 63:1990;340-344.
19. Murray A., McLaughlin N.B., Bourke J.P., Doig C.J., Furnisss S.S., Campbell R.W.F. Errors in manual measurement of QT intervals. Br. Heart J. 71:1994;386-390.
20. Higham P.D., Furniss S.S., Campbell R.W.F. QT-dispersion and components of the QT-interval in ischaemia and infarction. Br. Heart J. 73:1995;32-36.
21. Watanabe H., Hasegawa A., Shinozaki T.et al. Possible cardiac side effects of granisetron, an antiemetic agent, in patients with bone and soft-tissue sarcomas receiving cytotoxic chemotherapy. Cancer Chemother. Pharmacol. 35:1995;278-282.
22. Carmichael J. The Cardiovascular Safety of High-dose Intravenous Granisetron in Cancer Patients Receiving Highly Emetogenic Chemotherapy. 2002;MASCC, Boston. (abstr).
23. Baltzer L., Kris M.G., Hinkley L.et al. Reversible electrocardiographic interval prolongations following the specific serotonin antagonists ondansetron (OND) and dolasetron mesylate (DM). a possible drug class effect without sequelae? Proc. Am. Soc. Clin. Oncol. 13:1994;433. (abstr 1489).
24. Benedict C.R., Arbogast R., Martin L.et al. Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameter in normal volunteers. J. Cardiovasc. Pharmacol. 28:1996;53-59.
25. Grote T.H., Pineda L.F., Figlin R.A.et al. Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Cancer J. Sci. Am. 3:1997;45-51.
26. Rubenstein E.B., Gralla R.J., Hainsworth J.D.et al. Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Cancer. 79:1997;1216-1224.